

# Next Edge Bio-Tech Plus Fund

Annual Management Report of Fund Performance – 2016



**NEXTEDGE**  
CAPITAL

This annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements of the Next Edge Bio-Tech Plus Fund (the "Fund"). You may obtain a copy of the annual financial statements at your request, and at no cost, by calling (416) 775-3600 or toll-free at (877) 860-1080, by writing to us at Next Edge Capital Corp., 1 Toronto Street, Suite 200, Toronto, Ontario, M5C 2V6, Canada or by visiting our website at [www.nextedgecapital.com](http://www.nextedgecapital.com) or SEDAR at [www.sedar.com](http://www.sedar.com).

Unitholders may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

### **Caution Regarding Forward-looking Statements**

Certain portions of this report, including but not limited to, "Results of Operations" and "Recent Developments", may contain forward-looking statements about Next Edge Bio-Tech Plus Fund (the "Fund"), including its strategies, risks, expected performance and condition. All statements, other than statements of historical fact, that address activities, events or developments that Next Edge Capital Corp. (the "Manager") believe, expect or anticipate will or may occur in the future (including, without limitation, statements regarding any targeted returns, projections, forecasts, statements and future plans and objectives of the Fund) are forward-looking statements. These forward-looking statements reflect the current expectations, assumptions or beliefs of the Manager based on information currently available to the Fund.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Fund to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Fund.

Factors that could cause actual results or events to differ materially from current expectations include, among other things, changes in international financial and commodities markets, fluctuations in currency exchange and interest rates, illiquidity of portfolio investments, reduction in availability of leverage, default by counterparties, special risks arising from short sales and investments in forward contracts and other derivatives, unintentional trades, accuracy of analytical models, valuation risks, limitations on redemptions, tax consequences, changes in applicable laws and other risks associated with investing in securities and those factors discussed under the section entitled "Risk Factors" in the Fund's simplified prospectus.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Manager and the Fund disclaim any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Manager believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

# Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Management discussion of fund performance

## Investment Objective and Strategies

Next Edge Bio-Tech Plus Fund (the “Fund”) is a mutual fund established as a trust under the laws of the Province of Ontario by a declaration of trust dated December 1, 2014 made by Next Edge Capital Corp., as trustee. The Fund is divided into units of participation (“Units”) representing an interest in the Fund held by unitholders. The Fund has four classes of Units: Class A Units, Class A1 Units, Class F Units and Class F1 Units.

The Fund started investing according to its investment objective on February 17, 2015.

### *Investment Objective*

This Fund seeks short and long-term capital appreciation through the ownership of small and mid-capitalization biotechnology and healthcare companies based in Canada and the United States.

The Manager will not change the investment objectives of the Fund without the approval of a majority of Unitholders.

### *Investment Strategies*

The portfolio manager uses the following investment strategies to attempt to achieve the Fund’s investment objective:

- Holdings comprised of a mix of Canadian and US biomedical companies.
- Sector exposure includes biotechnology, Speciality Pharma, Medical Devices, Diagnostics, Drug Delivery, Bioinformatics and Agricultural and Healthcare Services.
- Derivatives are used for hedging purposes and return enhancement.

Investment decisions are made by:

- Focusing on companies in later stages of clinical development or early commercialization that meet specific criteria and whose data has been subjected to peer reviewed analysis.
- Managing the Fund in accordance with a risk-managed barbell methodology. This approach attempts to reduce overall portfolio volatility by: further reducing the risk associated with investments in a particular sector by placing option hedges on biotechnology indices; and exiting or hedging a particular position, should the applicable issuer be faced with event risks owing to expected upcoming factors/data/information.
- Collectively hedging to reduce the volatility of a traditionally volatile sector.

The Fund may invest in securities denominated in currencies other than Canadian dollars from time to time. The amount of such investments will vary but may exceed 50% of the net assets of the Fund at the time that such securities are purchased.

The Fund may invest in or use derivatives for hedging and non-hedging purposes in a manner consistent with the investment objective of the Fund and as permitted by applicable securities legislation. Derivatives to be used by the Fund may include, but are not limited to, non-exchange traded options, forward contracts, futures contracts and swaps.

The Fund may depart temporarily from its fundamental investment objectives and will likely invest in cash or cash equivalents in the event of adverse market, economic, political or other considerations.

The Fund is managed by Next Edge Capital Corp. (the “Manager”). The custodian, registrar, transfer agent and valuation agent of the Fund is RBC Investor & Treasury Services beginning May 9, 2016 and CIBC Mellon Trust Company as Custodian and Citigroup Fund Services Canada Inc. as registrar, transfer agent and valuation agent prior to May 9, 2016. The registered office of the Fund is located at 1 Toronto Street, Suite 200, Toronto, Ontario, Canada, M5C 2V6.

# Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Management discussion of fund performance (continued)

## Risk

For period ended December 31, 2014, the Fund held 100% of its net assets in cash. The Fund started investing according to its investment objective on February 17, 2015. Effective February 17, 2015, an investment in the Fund is subject to certain risk factors relating to the Fund, as detailed in its Simplified Prospectus. During the year ended December 31, 2016, there were no changes to the Fund that materially affected the overall risk level associated with an investment in the Fund.

## Results of Operations

The Fund experienced a decrease in its net assets during the years ended December 31, 2016:

Class of redeemable units	December 31, 2016 NAV per unit (CAD) <sup>1</sup>	December 31, 2015 NAV per unit (CAD) <sup>1</sup>	% return for year ended December 31, 2016 <sup>1</sup>
A <sup>2</sup>	8.98	9.86	-8.9%
A1 <sup>3</sup>	9.61	10.43	-7.9%
F <sup>3</sup>	9.56	10.40	-8.1%
F1 <sup>3</sup>	9.81	10.54	-6.9%

1. Net assets attributable to holders of redeemable units ("NAV", or "Net Assets").
2. Class A was opened on December 1, 2014. The first issuance of Class A units to external investors was on April 10, 2015.
3. The first issuance of Class A1, Class F, and Class F1 units was on January 21, 2015.

The Next Edge Bio-Tech Plus Fund (the "Fund") commenced trading according to its investment objective on February 17th, 2015 to provide investors with exposure to small-mid cap biotech stocks. The benchmark is a blend of 60% NASDAQ Biotechnology Index and 40% S&P/TSX Capped Healthcare Index. Both indices are heavily weighted in large capitalization companies which are not representative of the Fund's holdings in small-mid cap emerging healthcare companies.

For the year ended December 31st, 2016, the Fund substantially outperformed its benchmark due primarily to five holdings being acquired by an average over 100% takeover premiums, along with favorable clinical outcomes and development partnerships in other holdings. The sector itself performed poorly, and all the excess returns were due to stock selection. The correction in the Biotech sector which began in mid-2015 appears to have troughed in mid-2016, after declining -40% for the Nasdaq Biotech index, and -50% for the TSX Capped Healthcare index. The third quarter saw a spirited rebound off a severely oversold level, before surrender much of those gains in 4Q:2016 on healthcare policy uncertainty stemming from the US Elections.

The Fund is focused on investing in companies in the late-stage of clinical development of potentially breakthrough therapeutics. This development process is a decade-long, capital intensive journey with many binary obstacles along the way. The Fund targets investment in companies that have surpassed many of these hurdles, and the odds favor success and growth ahead. Since the sector low in mid-2016 the market has favored the companies we invest in. In contrast, capital starved small cap biotech companies have struggled with funding available at a high cost. Similarly, large capitalization BioPharma companies also struggled to perform, though well-funded, they are in need of growth, without which they will continue to experience multiple compression. Such is their need, for example, our largest 2016 holding, Medivation (MDVN) became the object of a takeover in spring. By the time it was consummated in August, five BioPharma companies were bidding up to \$14 billion for it. It implies four companies were left needing to seek acquisitions elsewhere to filling their pipelines. More of the Fund's holdings are expected to be the object of acquisitions during 2017.

The Fund is significantly positioned in companies that have either filed for FDA approval in 2016 or will file for approval during 2017. At the end of 2016, companies held expect to have filed for approval by the end of 2017, on up to 18 breakthrough therapeutics. There is considerable growth potential embedded in the portfolio. Furthermore, rather than spend a decade developing a new therapeutic, many large BioPharma companies will continue to source acquisitions for growth now. The Fund concluded the second half recovery by appreciating in 5 of the final 6 months.

## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Management discussion of fund performance (continued)

### Recent Developments

The opening months of 2017 has been favorable to Biotech in the US as it has been a leading performer. That is in contrast to a year ago when the sector experienced its 3rd worst quarter in its history. The Fund has continued to appreciate well above its benchmark, despite the cost of always present protective portfolio hedges serving as a drag on returns. Two of the fund's largest holdings face pivotal data readouts in Alzheimer's disease trials; the first will be held in April and the second in September. To the end of February, the Fund had appreciated in 7 of the last 8 months.

### Related Party Transactions

The Manager is responsible for the day-to-day operations of the Fund and provides management services to the Fund, including the marketing, promotion, and distribution of the Fund; transfer agency services; and unitholder reporting and servicing. In consideration of the management services, the Fund pays management fees, which are accrued for daily, to the Manager based on the average NAV of the applicable class of units of the Fund. Dealer compensation, or service fees, if any, are paid out of management fees and the Manager is not reimbursed for these payments.

Total management fees for the period ended December 31, 2016 amounted to \$73,888 (December 31, 2015: \$30,057) with \$4,760 in outstanding accrued fees due to the Manager at December 31, 2016 (December 31, 2015: \$1,194).

The Fund pays the Manager a quarterly performance fee if the percentage gain in the NAV per unit of a class exceeds the percentage gain or loss of the benchmark, provided that the NAV per unit is greater than all previous values in which a performance fee was paid. Total performance fees for the year ended December 31, 2016 amounted to nil (2015: \$76) with nil in outstanding accrued fees due to the Manager at December 31, 2016 (2015: nil).

The Manager incurs operating expenses on behalf of the Fund and is then reimbursed by the Fund for such expenses.

In 2014, the Manager also provided formation capital of \$10 to the Fund to establish it as a trust.

National Instrument 81-107 Independent Review Committee for Investment Funds ("NI 81-107") requires all publicly offered investment funds, such as the Fund, to establish an independent review committee ("IRC"). Consequently, the Manager has appointed three independent IRC members. The purpose of the IRC is to: (i) review and provide input on the Manager's written policies and procedures that deal with conflict of interest matters; (ii) consider and, if deemed appropriate, approve the Manager's decision on a conflict of interest matter that the Manager refers to the IRC for approval; and (iii) perform such other duties as may be required of the IRC under applicable Canadian securities laws. Additional information about the IRC is available in the Fund's prospectus. Fees are paid to the IRC members for the performance of their duties.

The total remuneration paid to members of the Independent Review Committee allocable to the Fund during the period ended December 31, 2016 was \$3,850 (2015: \$1,246). There were no outstanding payables relating to Independent Review Committee fees as at December 31, 2016 and 2015.

## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

### Financial highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the respective periods ended December 31, 2016 and 2015, and December 1 (inception date of the Fund) to December 31, 2014.

#### Class A<sup>4</sup> – Net Assets per unit (CAD)

For the period ended	Dec 31, 2016 <sup>1</sup>	Dec 31, 2015 <sup>2,4</sup>	Dec 31, 2014 <sup>2</sup>
Net Assets per unit, beginning of period	9.86	10.00	10.00
<b>(Decrease) Increase from operations</b>			
Total revenue	0.04	0.02	-
Total expenses	(0.64)	(0.80)	-
Realized gains (losses) for the period	0.45	(0.76)	-
Unrealized gains for the period	0.66	2.49	-
<b>Total increase from operations</b>	<b>0.51</b>	<b>0.96</b>	<b>-</b>
<b>Distributions</b>			
From net investment income (excluding dividends)	-	-	-
From dividends	-	-	-
From capital gains	-	-	-
Return of capital	-	-	-
<b>Total distributions</b>	<b>-</b>	<b>-</b>	<b>-</b>
Net Assets per unit, end of period <sup>3</sup>	8.98	9.86	10.00

#### Class A1<sup>5</sup> – Net Assets per unit (CAD)

For the period ended	Dec 31, 2016 <sup>1</sup>	Dec 31, 2015 <sup>2</sup>
Net Assets per unit, beginning of period	10.43	10.00
<b>(Decrease) Increase from operations</b>		
Total revenue	0.03	0.02
Total expenses	(0.44)	(0.58)
Realized gains for the period	0.25	0.20
Unrealized (losses) gains for the period	(0.87)	0.78
<b>Total (decrease) increase from operations</b>	<b>(1.03)</b>	<b>0.42</b>
<b>Distributions</b>		
From net investment income (excluding dividends)	-	-
From dividends	-	-
From capital gains	-	-
Return of capital	-	-
<b>Total distributions</b>	<b>-</b>	<b>-</b>
Net Assets per unit, end of period <sup>3</sup>	9.61	10.43

## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Financial highlights (continued)

### Class F<sup>5</sup> – Net Assets per unit (CAD)

For the period ended	Dec 31, 2016 <sup>1</sup>	Dec 31, 2015 <sup>2</sup>
Net Assets per unit, beginning of period	10.40	10.00
<b>Increase from operations</b>		
Total revenue	0.05	0.02
Total expenses	(0.57)	(0.82)
Realized gains (losses) for the period	0.51	(0.50)
Unrealized gains for the period	1.39	1.91
<b>Total increase from operations</b>	<b>1.38</b>	<b>0.62</b>
<b>Distributions</b>		
From net investment income (excluding dividends)	-	-
From dividends	-	-
From capital gains	-	-
Return of capital	-	-
<b>Total distributions</b>	<b>-</b>	<b>-</b>
Net Assets per unit, end of period <sup>3</sup>	9.56	10.40

### Class F1<sup>5</sup> – Net Assets per unit (CAD)

For the period ended	Dec 31, 2016 <sup>1</sup>	Dec 31, 2015 <sup>2</sup>
Net Assets per unit, beginning of period	10.54	10.00
<b>(Decrease) Increase from operations</b>		
Total revenue	0.05	0.03
Total expenses	(0.38)	(0.53)
Realized gains for the period	0.38	0.04
Unrealized (losses) gains for the period	(0.44)	0.80
<b>Total (decrease) increase from operations</b>	<b>(0.39)</b>	<b>0.34</b>
<b>Distributions</b>		
From net investment income (excluding dividends)	-	-
From dividends	-	-
From capital gains	-	-
Return of capital	-	-
<b>Total distributions</b>	<b>-</b>	<b>-</b>
Net Assets per unit, end of period <sup>3</sup>	9.81	10.54

## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

### Financial highlights (continued)

1. This information is derived from the Fund's audited financial statements for the period ended December 31, 2016. Information related to the period ended December 31, 2016 has been prepared in compliance with International Financial Reporting Standards as published by the International Accounting Standards Board.
2. This information is derived from the Fund's audited financial statements for the periods ended December 31, 2015 and 2014. Information related to the periods ended December 31, 2015 and 2014 have been prepared in compliance with International Financial Reporting Standards as published by the International Accounting Standards Board.
3. Net Assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is calculated based on the average number of units outstanding over the period. Therefore, the beginning of period Net Assets, the increase (decrease) from operations and distributions, if any, will not sum to the end of period Net Assets.
4. Class A units were first issued on inception date of the Fund on December 1, 2014, but the Fund did not start investing according to its mandate until February 17, 2015.
5. The first issuance of Class A1 and Class F1 units was on January 21, 2015. The first issuance of Class F units was on January 23, 2015.



## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Financial highlights (continued)

### Class A<sup>7</sup> – Ratios and Supplement Data:

For the period ended	December 31, 2016 <sup>3</sup>	December 31, 2015 <sup>4</sup>	December 31, 2014 <sup>4</sup>
Total NAV (CAD 000s) <sup>1</sup>	1,997	705	0.01
Number of units outstanding <sup>1</sup>	222,317	71,474	1
Management expense ratio <sup>2</sup>	4.86%	9.77%	-
Management expense ratio before waivers or absorptions <sup>2</sup>	4.86%	9.77%	-
Trading expense ratio <sup>5</sup>	2.07%	2.22%	-
Portfolio turnover rate <sup>6</sup>	173.12%	148.16%	-
NAV per unit (CAD)	8.98	9.86	10.00

### Class A1<sup>8</sup> – Ratios and Supplement Data:

For the period ended	December 31, 2016 <sup>3</sup>	December 31, 2015 <sup>4</sup>
Total NAV (CAD 000s) <sup>1</sup>	2,246	3,166
Number of units outstanding <sup>1</sup>	233,650	303,529
Management expense ratio <sup>2</sup>	3.63%	4.30%
Management expense ratio before waivers or absorptions <sup>2</sup>	3.63%	4.30%
Trading expense ratio <sup>5</sup>	2.07%	2.22%
Portfolio turnover rate <sup>6</sup>	173.12%	148.16%
NAV per unit (CAD)	9.61	10.43

### Class F<sup>8</sup> – Ratios and Supplement Data:

For the period ended	December 31, 2016 <sup>3</sup>	December 31, 2015 <sup>4</sup>
Total NAV (CAD 000s) <sup>1</sup>	2,591	341
Number of units outstanding <sup>1</sup>	271,119	32,773
Management expense ratio <sup>2</sup>	3.86%	7.14%
Management expense ratio before waivers or absorptions <sup>2</sup>	3.86%	7.14%
Trading expense ratio <sup>5</sup>	2.07%	2.22%
Portfolio turnover rate <sup>6</sup>	173.12%	148.16%
NAV per unit (CAD)	9.56	10.40

### Class F1<sup>8</sup> – Ratios and Supplement Data:

For the period ended	December 31, 2016 <sup>3</sup>	December 31, 2015 <sup>4</sup>
Total NAV (CAD 000s) <sup>1</sup>	1,742	1,254
Number of units outstanding <sup>1</sup>	177,567	119,014
Management expense ratio <sup>2</sup>	2.63%	3.65%
Management expense ratio before waivers or absorptions <sup>2</sup>	2.63%	3.65%
Trading expense ratio <sup>5</sup>	2.07%	2.22%
Portfolio turnover rate <sup>6</sup>	173.12%	148.16%
NAV per unit (CAD)	9.81	10.54

## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

### Financial highlights (continued)

1. This information is provided as at December 31, 2016, 2015 and 2014.
2. Management expense ratio is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average net asset value during the period. The management expense ratio is calculated in accordance with Part 15 of NI 81-106.
3. This information is derived from the Fund's audited financial statements for the period ended December 31, 2016. Information related to the period ended December 31, 2016 has been prepared in compliance with International Financial Reporting Standards as published by the International Accounting Standards Board.
4. This information is derived from the Fund's audited financial statements for the periods ended December 31, 2015 and 2014. Information related to the period ended December 31, 2015 and 2014 has been prepared in compliance with International Financial Reporting Standards as published by the International Accounting Standards Board.
5. The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net asset value during the period.
6. The Fund's portfolio turnover rate indicates how actively the Fund's portfolio manager manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the year. The higher the Fund's portfolio turnover rate in a year, the greater the trading costs payable by the Fund in the year, and the greater the chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high turnover rate and the performance of the Fund.
7. Class A units were first issued on inception date of the Fund on December 1, 2014, but the Fund did not start investing according to its mandate until February 17, 2015.
8. The first issuance of Class A1 and Class F1 units was on January 21, 2015. The first issuance of Class F units was on January 23, 2015.

## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Financial highlights (continued)

### Management Fees

For the year ended December 31, 2016 for its services to the Fund, the Manager was entitled to receive from the Fund, a management fee (the "Management Fee") at (up to) an annual rate of: (i) 2.25% of the portion of its Net Asset Value represented by the Class A units; (ii) 1.00% of the portion of its Net Asset Value represented by the Class A1 units; (iii) 1.25% of the portion of its Net Asset Value represented by the Class F units and (iv) 0.00% of the portion of its Net Asset Value represented by the Class F1 units, calculated daily and paid monthly in arrears, plus applicable taxes. The Manager uses these management fees to pay for sales and trailing commissions to registered dealers on the distribution of the Fund's units, investment advice, as well as for general administrative expenses such as overhead, salaries, rent, legal and accounting fees relating to the role of the Manager. The Fund started accruing for management fees on February 17, 2015.

Annual management fees, and a breakdown of the services received in consideration of the management fees, as a percentage of management fees, for the year ended December 31, 2016, are as follows:

Class of units	Annual Rates	As a percentage of management fees	
		Dealer Compensation	General administration, investment advice and profit
A	2.25%	44.44%	55.56%
A1	1.00%	100.00%	0.00%
F	1.25%	0.00%	100.00%
F1	0.00%	N/A	N/A

# Next Edge Bio-Tech Plus Fund

## Annual management report of fund performance – December 31, 2016

### Past performance


The performance information shown assumes that all distributions made by the Fund in the periods shown were reinvested in additional securities of the Fund. The performance information shown does not take into account sales, redemption, distribution or other optional charges that would have reduced returns or performance. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.

The Fund launched December 1, 2014 but did not trade according to its investment objectives until February 17, 2015. For the period ended December 31, 2014, for all classes, there was no net income or expense and no performance gain or loss.


Reported returns are from December 1, 2014 (the Fund's inception date) to December 31, 2014; January 1, 2015 to December 31, 2015; and January 1, 2016 to December 31, 2016.

### Year-by-Year Returns<sup>1,2</sup>


#### Class A<sup>1</sup>




#### Class A1<sup>2</sup>



#### Class F<sup>2</sup>



#### Class F1<sup>2</sup>



1. Class A units were first issued on inception date of the Fund on December 1, 2014, but the Fund did not start investing according to its mandate until February 17, 2015.
2. The first issuance of Class A1 and Class F1 units was on January 21, 2015. The first issuance of Class F units was on January 23, 2015.

# Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Past performance (continued)

## Annual Compound Returns

The following table shows the historical annualized compound returns for each Class of units of the Fund, for the periods ended December 31, 2016. It also shows, for the same periods, the returns for the S&P/TSX Capped Health Care Index (SPTSHC) and NASDAQ Biotechnology Index (NBI) obtained from Citigroup Fund Services Canada Inc. and RBC Investor & Treasury Services. There is no guarantee of performance and past or projected performance is not a reliable indicator of future performance. The latest data available at the time of production has been used. Returns may increase or decrease as a result of currency fluctuations.

<b>Percentage Return</b>	<b>1 year</b>	<b>Since Inception<sup>2</sup></b>
Class A units <sup>1</sup>	-8.9%	-5.0%
Class A1 units	-7.9%	-2.0%
Class F units	-8.1%	-2.3%
Class F1 units	-6.9%	-1.0%
Benchmark <sup>3</sup>	-30.9%	-14.9%

1. Class A units were first issued on inception date of the Fund on December 1, 2014, but the Fund did not start investing according to its mandate until February 17, 2015.
2. Inception dates used for calculation are December 1, 2014 for Class A; January 21, 2015 for Class A1, F1 and the benchmark; and January 23, 2015 for Class F.
3. The benchmark for the Fund is 40% of the percentage gain or loss of the S&P/TSX Capped Health Care Index (SPTSHC) plus 60% of the percentage gain or loss of the NASDAQ Biotechnology Index (NBI).

## Next Edge Bio-Tech Plus Fund

Semi-annual management report of fund performance – December 31, 2016

### Summary of investment portfolio

The following shows the underlying assets allocation by asset class and the top 25 holdings. The Underlying Assets and investment portfolio may change due to ongoing portfolio transactions.

<b>Portfolio by Asset Mix</b>	<b>% of Net Asset Value</b>	
	<b>Dec 31, 2016</b>	<b>Dec 31, 2015</b>
United States Equity	54.1%	54.6%
Canadian Equity	31.7%	36.9%
Cash and Cash Equivalents	9.8%	2.8%
International Equity	5.9%	2.9%
Equity Index Options	1.3%	0.1%
Equity Options	0.8%	1.0%
Canadian Bond	-%	1.9%
Currency Options	-%	0.4%
Total investments	103.6%	100.6%
Other net liabilities	(3.6%)	(0.6%)
Total net asset value	<b>100%</b>	<b>100%</b>

<b>Portfolio by Industry</b>	<b>% of Net Asset Value</b>	
	<b>Dec 31, 2016</b>	<b>Dec 31, 2015</b>
Pharmaceuticals	43.3%	26.8%
Pharmaceuticals and Biotechnology	15.9%	24.9%
Biotechnology	16.1%	26.5%
Healthcare equipment and services	12.6%	10.8%
Cash and Cash Equivalents	9.8%	2.8%
Healthcare	3.8%	4.3%
Equity Index Options	1.3%	0.1%
Equity Options	0.8%	1.0%
Corporate Bond	-%	1.9%
Energy – alternated sources	-%	1.1%
Currency Options	-%	0.4%
Total investments	103.6%	100.6%
Other net liabilities	(3.6%)	(0.6%)
Total net asset value	<b>100%</b>	<b>100%</b>

<b>Portfolio by Country</b>	<b>% of Net Asset Value</b>	
	<b>Dec 31, 2016</b>	<b>Dec 31, 2015</b>
United States	56.2%	56.1%
Canada	31.7%	38.8%
Cash and Cash Equivalents	9.8%	2.8%
Israel	3.2%	2.9%
Belgium	1.4%	-%
United Kingdom	1.3%	-%
Total investments	103.6%	100.6%
Other net liabilities	(3.6%)	(0.6%)
Total net asset value	<b>100%</b>	<b>100%</b>

## Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

Summary of investment portfolio (continued)

### Top 25 Long Positions<sup>1</sup>

<b>Issuer</b>	<b>% of Net Asset Value</b>
Acadia Pharmaceuticals Inc.	3.5%
Axovant Sciences Limited	3.4%
Neurotrope Inc.	3.3%
Extendicare Inc.	3.2%
RepliCel Life Sciences Inc. Rights March 01, 2017 - Strike Price \$0.85	3.2%
Synergy Pharmaceuticals Inc.	2.8%
Intercept Pharmaceuticals Inc.	2.7%
Promis Neurosciences Inc.	2.7%
Neurocrine Biosciences Inc.	2.4%
Portola Pharmaceuticals Inc.	2.4%
Sage Therapeutics Inc.	2.3%
Halozyme Therapeutics Inc.	2.2%
Intra-Cellular Therapies Inc.	2.1%
Concert Pharmaceuticals Inc.	2.1%
NeuroDerm Limited	2.1%
FibroGen Inc.	2.0%
Microbix Biosystems Inc.	2.0%
TSO3 Inc.	2.0%
Adamas Pharmaceuticals Inc.	1.9%
VTV Therapeutics Inc.	1.9%
Cipher Pharmaceuticals Inc.	1.9%
Centric Health Corp.	1.8%
Innoviva Inc.	1.8%
Xenon Pharmaceuticals Inc.	1.7%
Theratechnologies Inc.	1.7%

**Net Asset Value of Next Edge Bio-Tech Plus Fund as at December 31, 2016** **\$8,575,838**

1. The Fund held no short positions as at December 31, 2016.

# Next Edge Bio-Tech Plus Fund

Annual management report of fund performance – December 31, 2016

## General information

### MANAGER AND PRINCIPAL DISTRIBUTOR

Next Edge Capital Corp.  
1 Toronto Street, Suite 200  
Toronto, ON M5C 2V6

Telephone: (416) 775-3600  
Fax: (416) 775-3601  
Toll Free: 1 (877) 860-1080

[www.nextedgecapital.com](http://www.nextedgecapital.com)

### CUSTODIAN, REGISTRAR, TRANSFER AGENT AND VALUATION AGENT

*Effective May 9, 2016:*

RBC Investor & Treasury Services  
155 Wellington Street West  
Toronto, ON M5V 3H6

[www.rbcits.com](http://www.rbcits.com)

*Registrar, Transfer Agent and Valuation Agent until May 8, 2016:*

Citigroup Fund Services Canada Inc.  
5900 Hurontario Street, Suite 100  
Mississauga, ON L5R 0E8

*Custodian until May 8, 2016:*

CIBC Mellon Trust Company  
320 Bay Street  
Toronto, ON M5H 4A6

[www.cibcmellon.com](http://www.cibcmellon.com)

### BROKER

BMO Capital Markets Prime Brokerage  
100 King Street West, 6<sup>th</sup> Floor  
Toronto, ON M5X 1H3

[www.bmocm.com](http://www.bmocm.com)

### AUDITORS

Ernst & Young LLP  
222 Bay Street, P.O. Box 251  
Toronto, ON M5K 1J7

[www.ey.com](http://www.ey.com)

### LEGAL COUNSEL

Fasken Martineau DuMoulin LLP  
333 Bay Street, Suite 2400  
Toronto, ON M5H 2T6

[www.fasken.com](http://www.fasken.com)



**Next Edge Capital Corp.**  
1 Toronto St., Suite 200  
Toronto, ON M5C 2V6

Tel: 416 775-3600  
Fax: 416 775-3601

[www.nextedgecapital.com](http://www.nextedgecapital.com)